viewCaladrius Biosciences Inc

Caladrius Biosciences surges as it sells off majority stake in PCT

Caladrius is selling out to the junior partner in the joint venture and trousering US$75mln

US dollars
It's a handy cash boost for Caladrius

Cell-based gene therapy specialist Caladrius Biosciences Inc (NASDAQ:CLBS) has sold its 80.1% stake in its PCT subsidiary to Hitachi Chemical for US$75mln.

The news sent shares surging to US$6.04, up from US$5.10 at last night's close.

Caladrius said there is the potential for it to receive an additional cash payment of US$5 million if PCT achieves a certain revenue-based milestone.

PCT is an industry-leading cell therapy development and manufacturing services provider and is currently 19.9% owned by Hitachi Chemical.

Having sold out to the minority partner in the joint venture, Caladrius will now be a pure play cell therapeutics development company.

“Hitachi Chemical’s purchase of our remaining interest in PCT unlocks the value of this asset for our company both by transforming Caladrius into a well-capitalized pure play therapeutics development company and by eliminating our need to contribute the tens of millions of dollars of future capital investment in PCT needed for it to fully realize its cell therapy commercial manufacturing growth goals,” said David Mazzo, PhD, chief executive officer of Caladrius.

“The transaction provides considerable non-dilutive capital to fund the execution of our ongoing Phase 2 trial while also allowing us to exploit compelling therapeutic prospects,” he added.

Quick facts: Caladrius Biosciences Inc

Price: 1.82 USD

Market: NASDAQ
Market Cap: $35.17 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Water Tower Research President talks Energy and how Capstone Turbine is key...

Water Tower Research Co-Founder and President Shawn Severson joined Steve Darling from Proactive to share some insight about the Energy sector and how it is being viewed by users. Severson also told Proactive about Capstone Turbine and some things investors need to watch for from the company...

1 hour, 18 minutes ago

2 min read